Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Equity Income (2019 - 2020)

Avalo Therapeutics filings provide 2 years of Equity Income readings, the most recent being -$1.9 million for Q2 2020.

  • On a quarterly basis, Equity Income changed N/A to -$1.9 million in Q2 2020 year-over-year; TTM through Mar 2021 was -$1.9 million, a 126.24% decrease, with the full-year FY2020 number at $5.2 million, up 9556.6% from a year prior.
  • Equity Income hit -$1.9 million in Q2 2020 for Avalo Therapeutics, down from $7.1 million in the prior quarter.
  • In the past five years, Equity Income ranged from a high of $7.1 million in Q1 2020 to a low of -$1.9 million in Q2 2020.